Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates, ...
At the 2025 European Society of Medical Oncology (ESMO) Congress, held from October 17–21, results from the Phase III RC48-C016 study were presented, evaluating the combination of RemeGen Biosciences’ ...
Pfizer and Astellas Pharma said a treatment for certain bladder-cancer patients demonstrated positive topline results in a Phase 3 study. In the trial, the combination of Padcev with Merck & Co.'s ...
Keytruda and Padcev combination improved survival in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy. The KEYNOTE-905 trial showed significant event-free survival ...
AstraZeneca (NASDAQ:AZN) has announced positive results from a late-stage trial testing Imfinzi (durvalumab) combined with Bacillus Calmette-Guérin (BCG) therapy as a bladder cancer treatment. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback